


78%

Faster Time to Therapy

Accelerating Patient Throughput via Independent Digital Channels



EXECUTIVE SUMMARY

For a **leading global biopharma partner**, manual enrollment for complex rare disease therapies resulted in 63-day onboarding delays. RxWare deployed a **non-interruptive, independent digital channel** that condensed consent and financial workflows into a 6-minute session. This reduced time-to-therapy by 49 days (78% acceleration), realizing **\$6,713 in accelerated patient value** sooner per participant.

THE CLIENT & THE CHALLENGE

Success for high-cost rare disease therapies—**across oral, topical, and infusion methods**—is dependent on rapid enrollment into financial support programs.

The “Limbo” Effect

Manual hub procedures for Copay and Patient Assistance Programs (PAP) created 9-week onboarding bottlenecks.

Administrative Friction

Reliance on legacy systems caused significant patient abandonment before therapy initiation.

Unified, Mobile-First Workflow

By utilizing an **Independent Channel architecture**, RxWare captures **real-time behavioral data** to bypass traditional manual bottlenecks.



Tailored 6-Minute Enrollment

Patient completes all consent, financial, and hub enrollment data in one continuous mobile session.



Real-Time Financial Routing

System processes Copay eligibility and automatically triggers conditional auto-enrollment into the Patient Assistance Program (PAP) if needed.



Zero-Headcount Automation

Our unique architecture replaces weeks of administrative review with instant digital logic and zero manual intervention.



Audit-Ready Compliance

All validated data is instantly routed to the hub and compliance systems, eliminating paperwork delays.

QUANTIFIABLE RESULTS

TIME TO THERAPY

14 Days

(vs. 63 baseline)

78% acceleration in starting rare disease treatment.

ACCELERATED PATIENT VALUE

\$6,713

realized sooner

Dramatically improved patient throughput by 1.5 months.

ENROLLMENT EFFICIENCY

93%

Completion Rate

Minimized abandonment risk via a seamless, mobile-first experience.

CONSENT CONVERSION

35x

Increase

Exponentially improved digital consent capture vs. manual baselines.

CONCLUSION & FUTURE OUTLOOK

By replacing manual hurdles with an **Independent Channel architecture**, the brand secured a sustainable advantage in **Time-to-Therapy**. This automated enrollment framework ensures that complex, high-cost treatments reach patients with the speed and reliability required for a modern rare disease portfolio. By maximizing **patient throughput** and eliminating administrative “dead time,” RxWare enables access leaders to clear the path to therapy the moment a patient is referred.

For more information on accelerating time to therapy, please contact

commercial@rxware.io

RxWare